Table 4.
Risk factors for severe bleeding (n = 55) among all patients and eGFR groups.
| Risk Factors for Bleeding Event | ODDS RATIO | 95% CI | P |
|---|---|---|---|
| Univariate regression (n = 1420) | |||
| eGFR group (n = 1420) | - | - | 0.6469 |
| eGFR3 vs. eGFR2 (n = 1116) | 0.807 | 0.391–1.666 | 0.5624 |
| eGFR3 vs. eGFR1 (n = 621) | 0.675 | 0.295–1.543 | 0.3513 |
| eGFR2 vs. eGFR1 (n = 1103) | 0.836 | 0.438–1.594 | 0.5865 |
| ET (n = 546) | - | - | 0.2269 |
| eGFR3 vs. eGFR2 (n = 417) | 0.701 | 0.147–3.353 | 0.6563 |
| eGFR3 vs. eGFR1 (n = 238) | 0.326 | 0.066–1.602 | 0.1675 |
| eGFR2 vs. eGFR1 (n = 437) | 0.465 | 0.165–1.309 | 0.1471 |
| PV (n = 478) | - | - | 0.5219 |
| eGFR3 vs. eGFR2 (n = 376) | 0.431 | 0.095–1.944 | 0.2734 |
| eGFR3 vs. eGFR1 (n = 199) | 0.408 | 0.077–2.157 | 0.2916 |
| eGFR2 vs. eGFR1 (n = 381) | 0.948 | 0.329–2.729 | 0.9213 |
| MF (n = 396) | - | - | 0.6940 |
| eGFR3 vs. eGFR2 (n = 323) | 1.154 | 0.408–3.263 | 0.7867 |
| eGFR3 vs. eGFR1 (n = 184) | 2.029 | 0.398–10.337 | 0.3946 |
| eGFR2 vs. eGFR1 (n = 285) | 1.757 | 0.376–8.215 | 0.4736 |
| Diagnosis (n = 1420) | - | - | 0.4877 |
| ET vs. PV (n = 1024) | 0.736 | 0.381–1.422 | 0.3618 |
| ET vs. MF (n = 942) | 0.675 | 0.343–1.327 | 0.2543 |
| MF vs. PV (n = 874) | 1.091 | 0.569–2.091 | 0.7941 |
| Sex (female vs. male; n = 1420) | 0.533 | 0.305–0.933 | 0.0277 |
| Age at diagnosis (>60 vs. ≤60 years; n = 1416) | 0.756 | 0.432–1.323 | 0.0924 |
| Age at creatinine test (>60 vs. ≤60 years; n = 1420) | 0.784 | 0.457–1.344 | 0.3758 |
| JAK2V617F mutation (yes vs. no; n = 1315) | 1.759 | 0.813–3.809 | 0.1517 |
| Diabetes mellitus (yes vs. no; n = 1251) | 1.439 | 0.556–3.725 | 0.4534 |
| Arterial hypertension (yes vs. no; n = 956) | 1.302 | 0.678–2.499 | 0.4284 |
| Hyperlipoproteinemia (yes vs. no; n = 181) | 2.661 | 0.779–9.086 | 0.1182 |
| Leukocytes (>8.4 vs. ≤8.4 G/L; n = 1408) | 1.543 | 0.890–2.674 | 0.1223 |
| Platelets (>492 vs. ≤492 G/L; n = 1395) | 0.560 | 0.320–0.979 | 0.0421 |
| Uric acid (>5.7 vs. ≤5.7 mg/dL; n = 1012) | 1.685 | 0.869–3.269 | 0.1225 |
| Absolute neutrophil count (>5.48 vs. ≤5.48 G/L; n = 1254) | 1.697 | 0.963–2.992 | 0.0673 |
| Absolute monocyte count (>0.55 vs. ≤0.55 G/L; n = 1312) | 0.980 | 0.566–1.698 | 0.9424 |
| LDH (>267.5 vs. ≤267.5 U/L; n = 1356) | 3.292 | 1.748–6.201 | 0.0002 |
| CRP (>1.4 vs. ≤1.4 mg/L; n = 356) | 0.868 | 0.351–2.150 | 0.7603 |
| MPN therapy (yes vs. WW; n = 1215) | 1.694 | 0.927 -3.095 | 0.0865 |
| Antithrombotic therapy (yes vs. WW; n = 1251) | 0.903 | 0.500–1.628 | 0.7333 |
| Multiple regression (n = 1335) * | |||
| LDH (>267.5 vs. ≤267.5 U/L; n = 1356) | 3.292 | 1.748–6.201 | 0.0002 |
* Initial model including sex, platelets, and LDH. Bolded values indicate significant odds ratios and significant p values.